Page 298 - Drug Class Review
P. 298
Page 179 of 205
Drug Effectiveness Review Project
To determine whether oral TAC improves the symptoms of patients with mild to moderate AD
Shire Pharmaceuticals and Parke-Davis Research Laboratories
placebo N/A 12 weeks 76 AD diagnosed by NINCDS/ADRDA; MMSE > 10; CDRS of 1 or 2 Evidence of concurrent illness (cerebral infarction, including evidence on CT scan, hepatic disease, clinical depression or other psychiatric diagnoses); lacked a reliable caregiver Other medications allowed if they were not likely to interfere with or confuse the interpretation of the
Alzheimer Drugs Authors: Wood et al. 69 Year: 1994 Country: UK Study design: RCT Setting: Multi-center (memory and psychogeriatric clinics) Sample size: 154 tacrine 80 mg/d 12 weeks 78 expected actions of TAC
Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
